Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
Open Access
- 1 April 2025
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 221, 115397
Abstract
No abstract availableKeywords
Funding Information
- Memorial Sloan Kettering Cancer Center (P30 CA008748)
- Genentech Foundation
This publication has 21 references indexed in Scilit:
- Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast CancerNew England Journal of Medicine, 2024
- Capivasertib in Hormone Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2023
- Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαJournal of Medicinal Chemistry, 2022
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyThe Lancet Oncology, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast CancerInternational Journal of Breast Cancer, 2020
- Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2019
- Treatment for the endocrine resistant breast cancer: Current options and future perspectivesThe Journal of Steroid Biochemistry and Molecular Biology, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokineticsEuropean Journal of Cancer, 2008